ICI‐based combination therapy has showed inspiring clinical outcomes in NSCLC patients with EGFR mutations after resistance to EGFR‐TKI treatment, especially in patients with the EGFR L858R mutation. Here, EGFR is linked to non-small cell lung carcinoma.